Saltar al contenido
Merck

Metformin increases blood flow and forearm glucose uptake in a group of non-obese type 2 diabetes patients.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme (2006-08-31)
F O Magalhães, L M B Gouveia, M T C G Torquato, G M G F Paccola, C E Piccinato, M C Foss
RESUMEN

The present study was designed to determine the effects of metformin on the forearm glucose uptake and blood flow after an oral glucose challenge. Eleven normal subjects, and ten non-obese type 2 diabetes patients without medication of anti-hyperglycemic drug and with medication of metformin for four weeks, were studied after an overnight fast (12-14 h) and 3 hours after ingestion of 75 g of glucose. Peripheral glucose metabolism was analyzed by the forearm technique combined with indirect calorimetry. The forearm glucose uptake increased in diabetes patients taking metformin (63.5+/-9.1 VS. 39.1+/-5.3 mg/100 ml FA. 3 h). The increase of forearm glucose uptake was due to increase of blood flow. The glucose oxidation was greater in the group treated with metformin, compared to the same group without anti-hyperglycemic drug (19.3+/-2.6 VS. 7.7+/-2.6 mg/100 ml FA. 3 hrs). The free fatty acids were higher in diabetes patients, which normalized after taking metformin. In conclusion, it was found that in these participants metformin acts in insulin resistance; it increases glucose muscle uptake and blood flow. The enhancement of blood flow and lower free fatty acids, not described yet, could be direct effects of the drug or due to reduced glucose toxicity. These positive effects must be responsible for the improvement in vascular function.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Supelco
1,1-Dimetilbiguanida hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
1,1-Dimetilbiguanida hydrochloride, 97%
Supelco
Metformin hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®
1,1-Dimetilbiguanida hydrochloride, European Pharmacopoeia (EP) Reference Standard